The DOI matches its OpenAlex record; 20 of the 20 references it cites were found in a registry or an index.
Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
Abstract
PURPOSE: Preclinical studies have shown good anticancer activity following targeting of a polymer bearing doxorubicin with galactosamine (PK2) to the liver. The present phase I study was devised to determine the toxicity, pharmacokinetic profile, and targeting capability of PK2. PATIENTS AND METHODS: Doxorubicin was linked via a lysosomally degradable tetrapeptide sequence to N-(2-hydroxypropyl)methacrylamide copolymers bearing galactosamine. Targeting, toxicity, and efficacy were evaluated in 31 patients with primary (n = 25) or metastatic (n = 6) liver cancer. Body distribution of the radiolabelled polymer conjugate was assessed using gamma-camera imaging and single-photon emission computed tomography. RESULTS: The polymer was administered by intravenous (i.v.) infusion over 1 hour, repeated every 3 weeks. Dose escalation proceeded from 20 to 160 mg/m(2) (doxorubicin equivalents), the maximum-tolerated dose, which was associated with severe fatigue, grade 4 neutropenia, and grade 3 mucositis. Twenty-four hours after administration, 16.9% +/- 3.9% of the administered dose of doxorubicin targeted to the liver and 3.3% +/- 5.6% of dose was delivered to tumor. Doxorubicin-polymer conjugate without galactosamine showed no targeting. Three hepatoma patients showed partial responses, with one in continuing partial remission 47 months after therapy. CONCLUSION: The recommended PK2 dose is 120 mg/m(2), administered every 3 weeks by IV infusion. Liver-specific doxorubicin delivery is achievable using galactosamine-modified polymers, and targeting is also seen in primary hepatocellular tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Self-citationStone, P., Richardson, A., Ream, E., Smith, A. G., Kerr, D. J., & Kearney, N. (2000) · Annals of Oncology · doi:10.1023/a:1008318932641 · Cited by 438
Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour, L. W. (1992) · PubMed · Cited by 374
Self-citationSchwartz, A. L., Fridovich, S. E., & Lodish, H. F. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34710-0 · Cited by 364
Characterization of the asialoglycoprotein receptor in a continuous hepatoma line.
Schwartz, A. L., Fridovich, S. E., Knowles, B. B., & Lodish, H. F. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52477-2 · Cited by 272
Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin
Rihova, B., Bilej, M., Vetvicka, V., Ulbrich, K., Strohalm, J., Kopecek, J., & Duncan, R. (1989) · Biomaterials · doi:10.1016/0142-9612(89)90075-6 · Cited by 192
Preclinical evaluation of polymer-bound doxorubicin
Duncan, R., Seymour, L. W., O'Hare, K. B., Flanagan, P. A., Wedge, S., Hume, I. C., Ulbrich, K., Strohalm, J., Subr, V., Spreafico, F., et al. (1992) · Journal of Controlled Release · doi:10.1016/0168-3659(92)90088-9 · Cited by 187
Self-citationJulyan, P. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00124-2 · Cited by 180
Self-citationDUNCAN, R., Seymour, L. W., Scarlett, L., LLOYD, J., Rejmanová, P., & Kopeček, J. (1986) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(86)90120-0 · Cited by 130
Self-citationSeymour, L. W., Ulbrich, K., Wedge, S. R., Hume, I. C., Strohalm, J., & Duncan, R. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.190 · Cited by 117
Self-citationCummings, J., & McArdle, C. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.141 · Cited by 109
Ulbrich, K., Koňák, Č., Tuzar, Z., & Kopec̆ek, J. (1987) · Die Makromolekulare Chemie · doi:10.1002/macp.1987.021880604 · Cited by 93
Endocytosis via galactose receptors in vivo
Schlepper‐Schäfer, J., Hülsmann, D., Djovkar, A., Meyer, H. E., Herbertz, L., Kolb, H., & Kolb-Bachofen, V. (1986) · Experimental Cell Research · doi:10.1016/0014-4827(86)90602-6 · Cited by 76
Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice
Nishikawa, M., Ohtsubo, Y., Ohno, J., Fujita, T., Koyama, Y., Yamashita, F., Hashida, M., & Sezaki, H. (1992) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(92)90136-p · Cited by 70
Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma
Hyodo, I., Mizuno, M., Yamada, G., & Tsuji, T. (1993) · Liver International · doi:10.1111/j.1600-0676.1993.tb00611.x · Cited by 55
Soluble polymers for lectin-mediated drug targeting
Seymour, L. W. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90007-8 · Cited by 49
Self-citationIn vivo quantification of receptor-mediated uptake of asialoglycoproteins by rat liver.
Pardridge, W. M., Herle, A. J. V., Naruse, R. T., Fierer, G., & Costin, A. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33148-x · Cited by 46
Mesangial cells possess an asialoglycoprotein receptor with affinity for human immunoglobulin A.
Gómez‐Guerrero, C., Duque, N., & Egido, J. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v94568 · Cited by 43
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Metadata
- Authors
- Seymour, L. W., Ferry, D. R., Anderson, D., Hesslewood, S., Julyan, P. J., Poyner, R., Doran, J., Young, A., Burtles, S. S., & Kerr, D. J.
- Venue
- Journal of Clinical Oncology
- Publisher
- Lippincott Williams & Wilkins
- Published
- 2002-03-15
- Volume
- 20
- Issue
- 6
- Pages
- 1668-1676
- ISSN
- 0732-183X (ISSN-L)
- OpenAlex
- W1978183755
- Cited by
- 435
- References
- 20
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.